SecBot SecBot

PROK

PROKIDNEY CORP.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. E9· CIK 0001850270 Biotech & Drug Discovery
$1.04 −0.00 (−0.48%)
Nov 16 4:00 PM ET · prev $1.04
Market cap
$347.7M
Small cap
Consensus
Buy
69% Buy or better · 13 analysts
Median target
🔒 Subscribers only
1 year
−53.8%
from $2.25 · Nov 17
30 days
−25.4%
from $1.39
52-week range
$1.04–2.57
at the low
Avg volume 20D
1.42M
Nov 2 spike 7.30M
Short interest
24.34M
≈8.1% of shares · −0.9%
Days to cover
22.5
at average volume
Insider net
−$1.1M
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 5 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 7/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $1.1M.

  • InstitutionsBULLISH

    Q3 2026: 20 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    9 of 13 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −0.9% to 24.34M shares. 22.5 days to cover, ≈8.1% of shares.

  • TrendDOWNTREND

    31% below its 50-day average. New closing low $1.04 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD7,971,695$13.2M
GEODE CAPITAL MANAGEMENT, LLCADD3,590,979$6.0M
STATE STREET CORPADD1,810,345$3.0M
VANGUARD CAPITAL MANAGEMENT LLCADD1,726,762$2.9M
VANGUARD FIDUCIARY TRUST COADD982,525$1.6M
VANGUARD PORTFOLIO MANAGEMENT LLCADD761,533$1.3M
Nuveen, LLCADD154,892$257.1K
BARCLAYS PLCDOUBLED85,332$141.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 69% rate it Buy or better
Strong Buy5Buy4Hold3Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 28, 2026Citigroup
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

5 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$1.1M
sold · 1 insider
DateInsiderTypeValue
Nov 2, 2026
Culleton Bruce
Chief Executive Officer
Nov 2, 2026
AWARD500,000 sh
Oct 28, 2026
Weber Darin J.
Chief Regulatory Officer
Oct 28, 2026
CONVERT200,000 sh
Oct 28, 2026
Weber Darin J.
Chief Regulatory Officer
Oct 28, 2026
CONVERT200,000 sh
Oct 28, 2026
Weber Darin J.
Chief Regulatory Officer
Oct 28, 2026
CONVERT200,000 sh
Aug 20, 2026
Pereira Brian JG
Director
Aug 20, 2026
SELL$38.4K
Aug 20, 2026
Pereira Brian JG
Director
Aug 20, 2026
SELL$316.6K
Aug 19, 2026
Pereira Brian JG
Director
Aug 19, 2026
SELL$39.0K
Aug 19, 2026
Pereira Brian JG
Director
Aug 19, 2026
SELL$321.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next QNoneNoneNo data$200.0K
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
24,336,295
shares short
-0.9%
vs prior settlement
22.5
days to cover
≈8.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
ProKidney reported Q3 2026 results with no revenue and a net loss of $51.8 million, while cash burn continues with…
PRESS-RELEASE · Impact 7/10
Nov 12, 2026 Earnings
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
WINSTON-SALEM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
Nov 12, 2026 SEC
ProKidney Corp. filed a 424B5 prospectus supplement establishing a $200 million at-the-market (ATM) equity facility…
424B5 · Impact 6/10
Nov 12, 2026 SEC
ProKidney Corp.'s universal shelf registration (File No. 333-299700) became effective on November 10, 2026. This…
EFFECT · Impact 5/10
Nov 2, 2026 Insider
Culleton Bruce was granted 500,000 shares
Chief Executive Officer
Oct 28, 2026 Insider
Weber Darin J. acquired 200,000 shares
Chief Regulatory Officer
Oct 28, 2026 Insider
Weber Darin J. disposed of 200,000 shares
Chief Regulatory Officer
Oct 22, 2026 Press
ProKidney announced a virtual KOL event on October 27, 2026, featuring Dr. Katherine Tuttle to discuss new insights…
Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 12, 2026
Earnings
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
WINSTON-SALEM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage…
Nov 9, 2026
Earnings date
PROK Q3 2026 Earnings Scheduled · 2026-11-09
Oct 22, 2026
FDA
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage…
Oct 22, 2026
Press release
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial...
Oct 2, 2026
Press release
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage…

SecBot reports

11 filings · 2 press releases · 0 bullish · 5 bearish · 6 neutral
All PROK filing & press-release reports (13)